US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

1.73

-0.0300-1.70%

Post-market: 1.730.00000.00%16:00 EDT

Volume:83.59K

Turnover:143.33K

Market Cap:11.52M

PE:-0.36

High:1.80

Open:1.73

Low:1.67

Close:1.76

52wk High:12.40

52wk Low:0.6201

Shares:6.66M

Float Shares:5.84M

Volume Ratio:0.27

T/O Rate:1.43%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.7656

EPS(LYR):-8.3501

ROE:-660.08%

ROA:-95.77%

PB:2.48

PE(LYR):-0.21

Loading ...

Overview Company News Filings

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

FibroBiologics presents CYPS317 preclinical psoriasis data showing durable immunomodulation

Press Release: FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting

Fibrobiologics Inc - Files Provisional Patent Application for Oral Fibroblast Therapeutics

THOMSON REUTERS

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

FibroBiologics expands fibroblast-based platform to target Hantavirus

Fibrobiologics Shares Down 13%

THOMSON REUTERS

Fibrobiologics Shares NOW Down 15% Premarket at 99 Cents

THOMSON REUTERS

FibroBiologics expands fibroblast platform to target Hantavirus pulmonary syndrome

Fibrobiologics Advancing Development of a Fibroblast Treatment for Hantavirus

THOMSON REUTERS

Fibrobiologics Inc - to Initiate Discussions With Regulators for Hps Clinical Evaluation

THOMSON REUTERS

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

FibroBiologics boosts ATM equity offering capacity to USD 7.5 million

Fibrobiologics Inc - Increases Atm Offering to Aggregate $7.5 Mln on May 5, 2026 - SEC Filing

THOMSON REUTERS

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics Grants Stock Options to Key Executives

FibroBiologics grants CEO 92,410 stock options, executives 61,607 each at $1.38

FibroBiologics reports preclinical burn-wound data for fibroblast spheroid therapy

FibroBiologics Cut to Hold From Buy by Maxim Group

FibroBiologics releases CYWC628 drug product for Phase 1/2 diabetic foot ulcer trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/FBLG/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBLG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":1.73,"timestamp":1789070400000,"preClose":1.76,"halted":0,"volume":83593,"hourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.73,"latestTime":"16:00 EDT","volume":4,"amount":6.92,"timestamp":1789070413411,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01704545454545456,"floatShares":5843116,"shares":6658193,"eps":-4.765638,"marketStatus":"Post-Mkt","change":-0.03,"latestTime":"09-10 16:03:53 EDT","open":1.73,"high":1.7963,"low":1.6713,"amount":143332,"amplitude":0.071023,"askPrice":1.76,"askSize":4,"bidPrice":1.66,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-4.765638,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":4,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":1.76,"preHourTrading":{"tag":"盘前","latestPrice":1.8,"preClose":1.76,"latestTime":"07:48 EDT","volume":19,"amount":33.6399997,"timestamp":1789040904565,"change":0.04,"changeRate":0.022727,"amplitude":0.022727},"postHourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.73,"latestTime":"16:00 EDT","volume":4,"amount":6.92,"timestamp":1789070413411,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.27494},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","floatShares":5843116,"roa":"-95.77%","roe":"-660.08%","lyrEps":-8.3501,"volumeRatio":0.27494,"shares":6658193,"dividePrice":0,"high":1.7963,"amplitude":0.071023,"preClose":1.76,"low":1.6713,"week52Low":0.62005,"pbRate":"2.48","week52High":12.4,"institutionHeld":0,"latestPrice":1.73,"committee":0.984127,"eps":-4.765638,"divideRate":0,"volume":83593,"delay":0,"ttmEps":-4.765638,"open":1.73,"prevYearClose":4.498,"prevWeekClose":1.81,"prevMonthClose":1.72,"prevQuarterClose":0.9477,"fiveDayClose":1.95,"twentyDayClose":1.11,"sixtyDayClose":0.893},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBLG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-31","symbol":"FBLG","fiscalQuarterEnding":"2026/06","expectedEps":-0.93,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785470400000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-04-30","symbol":"FBLG","fiscalQuarterEnding":"2026/03","expectedEps":-1.26,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777521600000,"reportTimeType":"post","actualEps":-1.33},{"market":"US","date":"2026-03-30","symbol":"FBLG","defaultRemindTime":1774877400000,"type":"split","dateTimestamp":1774843200000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2026-02-24","symbol":"FBLG","fiscalQuarterEnding":"2025/12","expectedEps":-0.09,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771909200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2025-10-31","symbol":"FBLG","fiscalQuarterEnding":"2025/09","expectedEps":-0.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1761883200000,"reportTimeType":"post","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBLG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBLG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1777953600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FBLG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FBLG","date":"2026-09-09","current":-0.363015,"percent":0.833861,"low":-68.573467,"twenty":-5.875972,"median":-2.853034,"eighty":-0.860566,"high":-0.181252,"avg":-5.788768,"sd":9.527463,"marketCap":11385510},"quantilePoints":[{"date":"2024-02-02","current":-68.573467,"twenty":-68.573467,"median":-68.573467,"eighty":-68.573467,"marketCap":568611190},{"date":"2024-02-09","current":-30.642544,"twenty":-58.777258,"median":-48.452053,"eighty":-34.01244,"marketCap":254087971},{"date":"2024-02-16","current":-50.313332,"twenty":-58.777258,"median":-50.313332,"eighty":-30.642544,"marketCap":417198153},{"date":"2024-02-23","current":-47.413654,"twenty":-56.896385,"median":-48.5892,"eighty":-33.338461,"marketCap":393154022},{"date":"2024-03-01","current":-25.741365,"twenty":-54.984165,"median":-48.491237,"eighty":-33.338461,"marketCap":424346408},{"date":"2024-03-08","current":-19.47356,"twenty":-53.244359,"median":-47.492024,"eighty":-25.717713,"marketCap":321021631},{"date":"2024-03-15","current":-20.892685,"twenty":-51.363486,"median":-37.245189,"eighty":-20.955758,"marketCap":344415920},{"date":"2024-03-22","current":-23.849198,"twenty":-50.446561,"median":-28.99678,"eighty":-20.813845,"marketCap":393154022},{"date":"2024-03-28","current":-23.159345,"twenty":-50.219289,"median":-25.741365,"eighty":-20.93999,"marketCap":381781799},{"date":"2024-04-05","current":-22.469492,"twenty":-49.216157,"median":-24.637601,"eighty":-21.160743,"marketCap":370409575},{"date":"2024-04-12","current":-22.311811,"twenty":-48.471645,"median":-23.652097,"eighty":-21.298713,"marketCap":367810209},{"date":"2024-04-19","current":-21.700799,"twenty":-48.064123,"median":-23.20862,"eighty":-21.030656,"marketCap":357737668},{"date":"2024-04-26","current":-23.021374,"twenty":-47.63309,"median":-22.804563,"eighty":-21.030656,"marketCap":379507354},{"date":"2024-05-03","current":-13.245174,"twenty":-47.445002,"median":-22.479347,"eighty":-20.675875,"marketCap":218346696},{"date":"2024-05-10","current":-17.22661,"twenty":-43.252224,"median":-22.05558,"eighty":-19.871704,"marketCap":283980674},{"date":"2024-05-17","current":-17.017594,"twenty":-36.598639,"median":-21.769784,"eighty":-19.221271,"marketCap":383406402},{"date":"2024-05-24","current":-16.310932,"twenty":-31.990502,"median":-21.661379,"eighty":-18.255477,"marketCap":367485289},{"date":"2024-05-31","current":-17.767522,"twenty":-29.984238,"median":-21.543118,"eighty":-17.827098,"marketCap":400302277},{"date":"2024-06-07","current":-14.972667,"twenty":-28.19741,"median":-21.306597,"eighty":-17.252609,"marketCap":337334178},{"date":"2024-06-14","current":-10.427133,"twenty":-26.746956,"median":-21.178482,"eighty":-16.659936,"marketCap":234923317},{"date":"2024-06-21","current":-7.769521,"twenty":-25.741365,"median":-20.932105,"eighty":-16.368618,"marketCap":175047318},{"date":"2024-06-28","current":-6.767471,"twenty":-25.694061,"median":-20.88283,"eighty":-16.302279,"marketCap":152471122},{"date":"2024-07-05","current":-6.143005,"twenty":-25.43783,"median":-20.64631,"eighty":-15.81876,"marketCap":138401898},{"date":"2024-07-12","current":-7.689204,"twenty":-24.673079,"median":-20.183123,"eighty":-14.136173,"marketCap":173237756},{"date":"2024-07-15","current":-7.514809,"twenty":-24.649427,"median":-20.094427,"eighty":-13.517924,"marketCap":169308652},{"date":"2024-08-02","current":-7.974576,"twenty":-24.625775,"median":-20.005732,"eighty":-13.175194,"marketCap":179667198},{"date":"2024-08-09","current":-4.080921,"twenty":-24.140907,"median":-19.700225,"eighty":-10.836667,"marketCap":79459622},{"date":"2024-08-16","current":-2.166861,"twenty":-23.730937,"median":-18.842837,"eighty":-9.439605,"marketCap":42190950},{"date":"2024-08-23","current":-2.546062,"twenty":-23.640271,"median":-18.638558,"eighty":-7.79743,"marketCap":49574366},{"date":"2024-08-30","current":-2.915474,"twenty":-23.407692,"median":-18.172694,"eighty":-7.552859,"marketCap":56767191},{"date":"2024-09-06","current":-3.368187,"twenty":-23.218475,"median":-17.767522,"eighty":-6.924314,"marketCap":65581972},{"date":"2024-09-13","current":-5.722296,"twenty":-23.104157,"median":-17.428613,"eighty":-6.143005,"marketCap":111418835},{"date":"2024-09-20","current":-5.722296,"twenty":-22.93465,"median":-17.22661,"eighty":-5.90745,"marketCap":111418835},{"date":"2024-09-27","current":-5.686079,"twenty":-22.765143,"median":-16.563311,"eighty":-5.873037,"marketCap":110713652},{"date":"2024-10-04","current":-4.798761,"twenty":-22.619289,"median":-16.368618,"eighty":-5.722296,"marketCap":93436681},{"date":"2024-10-11","current":-4.20118,"twenty":-22.481318,"median":-16.080185,"eighty":-5.265962,"marketCap":81801170},{"date":"2024-10-18","current":-6.012033,"twenty":-22.40642,"median":-15.807485,"eighty":-5.066768,"marketCap":117060295},{"date":"2024-10-25","current":-5.215258,"twenty":-22.209319,"median":-15.237992,"eighty":-5.131958,"marketCap":101546280},{"date":"2024-10-31","current":-5.342017,"twenty":-22.020102,"median":-13.586112,"eighty":-5.110228,"marketCap":104014418},{"date":"2024-11-08","current":-6.464746,"twenty":-21.866364,"median":-12.649071,"eighty":-5.128337,"marketCap":125875076},{"date":"2024-11-15","current":-5.477931,"twenty":-21.799349,"median":-10.768411,"eighty":-5.146445,"marketCap":97392141},{"date":"2024-11-22","current":-4.698155,"twenty":-21.716567,"median":-9.773622,"eighty":-5.018763,"marketCap":83528491},{"date":"2024-11-29","current":-5.107537,"twenty":-21.700799,"median":-9.003931,"eighty":-5.016064,"marketCap":90806907},{"date":"2024-12-06","current":-4.639671,"twenty":-21.661379,"median":-7.895306,"eighty":-4.997955,"marketCap":82488717},{"date":"2024-12-13","current":-4.425233,"twenty":-21.562828,"median":-7.720912,"eighty":-4.979847,"marketCap":78676213},{"date":"2024-12-20","current":-3.957367,"twenty":-21.543118,"median":-7.546517,"eighty":-4.853087,"marketCap":70358023},{"date":"2024-12-27","current":-4.50321,"twenty":-21.511582,"median":-7.203145,"eighty":-4.778145,"marketCap":80062578},{"date":"2025-01-03","current":-3.869642,"twenty":-21.385437,"median":-6.905845,"eighty":-4.698155,"marketCap":68798363},{"date":"2025-01-10","current":-4.065278,"twenty":-21.306597,"median":-6.609614,"eighty":-4.652603,"marketCap":72276579},{"date":"2025-01-17","current":-3.769263,"twenty":-21.298713,"median":-6.286711,"eighty":-4.50321,"marketCap":67013721},{"date":"2025-01-24","current":-3.157497,"twenty":-21.243525,"median":-6.193118,"eighty":-4.433031,"marketCap":56137148},{"date":"2025-01-31","current":-3.295638,"twenty":-21.050366,"median":-6.140899,"eighty":-4.36675,"marketCap":58593149},{"date":"2025-02-07","current":-3.157497,"twenty":-20.955758,"median":-6.004281,"eighty":-4.203103,"marketCap":56137148},{"date":"2025-02-14","current":-2.545732,"twenty":-20.888743,"median":-5.948653,"eighty":-4.068407,"marketCap":45260576},{"date":"2025-02-21","current":-2.447061,"twenty":-20.872975,"median":-5.908467,"eighty":-3.946872,"marketCap":43506290},{"date":"2025-02-28","current":-2.348389,"twenty":-20.794135,"median":-5.885273,"eighty":-3.784683,"marketCap":41752004},{"date":"2025-03-07","current":-2.210248,"twenty":-20.498484,"median":-5.867165,"eighty":-3.670591,"marketCap":39296004},{"date":"2025-03-14","current":-2.109947,"twenty":-20.183123,"median":-5.776622,"eighty":-3.453513,"marketCap":37512750},{"date":"2025-03-21","current":-2.151728,"twenty":-20.183123,"median":-5.722296,"eighty":-3.368187,"marketCap":38255577},{"date":"2025-03-28","current":-2.130838,"twenty":-20.005732,"median":-5.595537,"eighty":-3.295638,"marketCap":37884163},{"date":"2025-04-04","current":-2.958372,"twenty":-19.926892,"median":-5.518575,"eighty":-3.165965,"marketCap":33018387},{"date":"2025-04-11","current":-2.748074,"twenty":-19.788921,"median":-5.342017,"eighty":-3.105834,"marketCap":30671251},{"date":"2025-04-17","current":-3.685286,"twenty":-19.647008,"median":-5.282987,"eighty":-3.104326,"marketCap":41131477},{"date":"2025-04-25","current":-4.361485,"twenty":-19.501154,"median":-5.215258,"eighty":-3.131377,"marketCap":48678537},{"date":"2025-05-02","current":-3.496805,"twenty":-18.968982,"median":-5.142823,"eighty":-3.15355,"marketCap":39027837},{"date":"2025-05-09","current":-2.900977,"twenty":-18.732461,"median":-5.107537,"eighty":-3.105179,"marketCap":32377800},{"date":"2025-05-16","current":-5.090366,"twenty":-18.693381,"median":-5.090366,"eighty":-3.095239,"marketCap":39027837},{"date":"2025-05-23","current":-4.291877,"twenty":-18.607387,"median":-5.049055,"eighty":-3.101704,"marketCap":32905823},{"date":"2025-05-30","current":-3.742916,"twenty":-18.421041,"median":-5.00701,"eighty":-3.104523,"marketCap":28696939},{"date":"2025-06-06","current":-4.262932,"twenty":-18.227882,"median":-4.979847,"eighty":-3.124991,"marketCap":32683900},{"date":"2025-06-13","current":-4.354259,"twenty":-18.018955,"median":-4.934576,"eighty":-3.149603,"marketCap":33384106},{"date":"2025-06-20","current":-3.674878,"twenty":-17.856887,"median":-4.868731,"eighty":-3.157497,"marketCap":28175292},{"date":"2025-06-27","current":-3.644169,"twenty":-17.748258,"median":-4.815121,"eighty":-3.160884,"marketCap":27939844},{"date":"2025-07-03","current":-3.132347,"twenty":-17.688614,"median":-4.795627,"eighty":-3.157497,"marketCap":24015708},{"date":"2025-07-11","current":-3.321721,"twenty":-17.510817,"median":-4.711647,"eighty":-3.13343,"marketCap":25467638},{"date":"2025-07-18","current":-3.531568,"twenty":-17.278608,"median":-4.698155,"eighty":-3.14171,"marketCap":27076534},{"date":"2025-07-25","current":-3.36062,"twenty":-17.22661,"median":-4.675331,"eighty":-3.157497,"marketCap":25765873},{"date":"2025-08-01","current":-3.260303,"twenty":-17.184807,"median":-4.665775,"eighty":-3.157497,"marketCap":24996742},{"date":"2025-08-08","current":-1.692292,"twenty":-16.92818,"median":-4.639671,"eighty":-3.111465,"marketCap":22377179},{"date":"2025-08-15","current":-1.862725,"twenty":-16.567638,"median":-4.558872,"eighty":-3.098103,"marketCap":24630815},{"date":"2025-08-22","current":-1.865576,"twenty":-16.533025,"median":-4.524553,"eighty":-3.074912,"marketCap":24668515},{"date":"2025-08-29","current":-1.964732,"twenty":-16.426305,"median":-4.50321,"eighty":-3.015849,"marketCap":25979645},{"date":"2025-09-05","current":-1.881416,"twenty":-16.368618,"median":-4.425233,"eighty":-2.962429,"marketCap":24877961},{"date":"2025-09-12","current":-1.789547,"twenty":-16.310932,"median":-4.376497,"eighty":-2.933582,"marketCap":23663176},{"date":"2025-09-19","current":-1.694826,"twenty":-16.29651,"median":-4.361485,"eighty":-2.897365,"marketCap":22410690},{"date":"2025-09-26","current":-1.709716,"twenty":-15.863859,"median":-4.348021,"eighty":-2.853034,"marketCap":22607569},{"date":"2025-10-03","current":-1.710666,"twenty":-15.863859,"median":-4.327761,"eighty":-2.748074,"marketCap":22620136},{"date":"2025-10-10","current":-1.544034,"twenty":-15.807485,"median":-4.261494,"eighty":-2.486529,"marketCap":20416767},{"date":"2025-10-17","current":-1.298839,"twenty":-15.630094,"median":-4.210794,"eighty":-2.348389,"marketCap":17174548},{"date":"2025-10-24","current":-1.301056,"twenty":-15.503317,"median":-4.186877,"eighty":-2.318853,"marketCap":17203870},{"date":"2025-10-31","current":-1.257339,"twenty":-14.972667,"median":-4.132817,"eighty":-2.297962,"marketCap":16625800},{"date":"2025-11-07","current":-0.932278,"twenty":-13.927049,"median":-4.072247,"eighty":-2.249717,"marketCap":17248077},{"date":"2025-11-14","current":-0.933669,"twenty":-13.245174,"median":-4.04235,"eighty":-2.172619,"marketCap":17273805},{"date":"2025-11-21","current":-0.902797,"twenty":-13.070223,"median":-4.004863,"eighty":-2.130838,"marketCap":16702642},{"date":"2025-11-28","current":-0.907742,"twenty":-12.733301,"median":-3.95212,"eighty":-2.105769,"marketCap":16794130},{"date":"2025-12-05","current":-0.861361,"twenty":-11.417566,"median":-3.918378,"eighty":-2.038689,"marketCap":15936036},{"date":"2025-12-12","current":-1.151904,"twenty":-11.10969,"median":-3.880347,"eighty":-1.962831,"marketCap":21311383},{"date":"2025-12-19","current":-0.864342,"twenty":-10.563644,"median":-3.855551,"eighty":-1.925449,"marketCap":15991199},{"date":"2025-12-26","current":-0.781519,"twenty":-10.366139,"median":-3.817676,"eighty":-1.905048,"marketCap":14458888},{"date":"2026-01-02","current":-0.80862,"twenty":-10.104734,"median":-3.784683,"eighty":-1.867667,"marketCap":14960285},{"date":"2026-01-09","current":-1.186504,"twenty":-9.756195,"median":-3.726488,"eighty":-1.863485,"marketCap":21951508},{"date":"2026-01-16","current":-1.21347,"twenty":-9.439605,"median":-3.689721,"eighty":-1.817994,"marketCap":22450406},{"date":"2026-01-23","current":-1.222459,"twenty":-8.832939,"median":-3.685286,"eighty":-1.804182,"marketCap":22616705},{"date":"2026-01-30","current":-1.226773,"twenty":-8.114091,"median":-3.670176,"eighty":-1.745069,"marketCap":22696529},{"date":"2026-02-06","current":-0.81653,"twenty":-7.942868,"median":-3.64061,"eighty":-1.71998,"marketCap":15106628},{"date":"2026-02-13","current":-0.884485,"twenty":-7.806733,"median":-3.5628,"eighty":-1.705851,"marketCap":16363851},{"date":"2026-02-20","current":-0.903181,"twenty":-7.769521,"median":-3.544415,"eighty":-1.692292,"marketCap":16709754},{"date":"2026-02-27","current":-1.025558,"twenty":-7.720912,"median":-3.492982,"eighty":-1.665999,"marketCap":19122546},{"date":"2026-03-06","current":-1.519667,"twenty":-7.689204,"median":-3.463009,"eighty":-1.553538,"marketCap":28335707},{"date":"2026-03-13","current":-1.232917,"twenty":-7.578225,"median":-3.43637,"eighty":-1.519667,"marketCap":22988964},{"date":"2026-03-20","current":-0.927678,"twenty":-7.514809,"median":-3.414459,"eighty":-1.43094,"marketCap":17297489},{"date":"2026-03-27","current":-0.797535,"twenty":-7.246713,"median":-3.39431,"eighty":-1.385333,"marketCap":14870838},{"date":"2026-04-02","current":-0.241073,"twenty":-7.177005,"median":-3.378022,"eighty":-1.359957,"marketCap":4495048},{"date":"2026-04-10","current":-0.336129,"twenty":-7.067291,"median":-3.359084,"eighty":-1.328997,"marketCap":6267453},{"date":"2026-04-17","current":-0.370229,"twenty":-6.822821,"median":-3.321721,"eighty":-1.299599,"marketCap":6903282},{"date":"2026-04-24","current":-0.367793,"twenty":-6.742593,"median":-3.30892,"eighty":-1.267223,"marketCap":6857865},{"date":"2026-05-01","current":-0.368753,"twenty":-6.533559,"median":-3.275657,"eighty":-1.232416,"marketCap":6875767},{"date":"2026-05-08","current":-0.345774,"twenty":-6.468368,"median":-3.258236,"eighty":-1.221308,"marketCap":6459054},{"date":"2026-05-15","current":-0.312154,"twenty":-6.322318,"median":-3.235952,"eighty":-1.201893,"marketCap":5831040},{"date":"2026-05-22","current":-0.303483,"twenty":-6.255297,"median":-3.19076,"eighty":-1.171044,"marketCap":5669067},{"date":"2026-05-29","current":-0.326606,"twenty":-6.214848,"median":-3.171598,"eighty":-1.119059,"marketCap":6100996},{"date":"2026-06-05","current":-0.309264,"twenty":-6.16305,"median":-3.157497,"eighty":-1.023143,"marketCap":5777049},{"date":"2026-06-12","current":-0.278626,"twenty":-6.143005,"median":-3.135055,"eighty":-0.995266,"marketCap":5204743},{"date":"2026-06-18","current":-0.231225,"twenty":-6.14132,"median":-3.119296,"eighty":-0.966672,"marketCap":4319289},{"date":"2026-06-26","current":-0.211918,"twenty":-6.088089,"median":-3.102557,"eighty":-0.949468,"marketCap":3958628},{"date":"2026-07-02","current":-0.261949,"twenty":-6.010483,"median":-3.098055,"eighty":-0.939027,"marketCap":4893215},{"date":"2026-07-10","current":-0.248856,"twenty":-6.001989,"median":-3.08079,"eighty":-0.932373,"marketCap":4648635},{"date":"2026-07-17","current":-0.242729,"twenty":-5.989422,"median":-3.058826,"eighty":-0.919078,"marketCap":4534174},{"date":"2026-07-24","current":-0.212583,"twenty":-5.964951,"median":-3.025992,"eighty":-0.912766,"marketCap":3971046},{"date":"2026-07-31","current":-0.207872,"twenty":-5.92149,"median":-2.981001,"eighty":-0.907742,"marketCap":3883041},{"date":"2026-08-07","current":-0.374406,"twenty":-5.913552,"median":-2.958372,"eighty":-0.904979,"marketCap":6791356},{"date":"2026-08-14","current":-0.422125,"twenty":-5.903382,"median":-2.937355,"eighty":-0.902462,"marketCap":7656921},{"date":"2026-08-21","current":-0.473514,"twenty":-5.885273,"median":-2.907657,"eighty":-0.890492,"marketCap":8589068},{"date":"2026-08-28","current":-0.546927,"twenty":-5.885273,"median":-2.888543,"eighty":-0.871962,"marketCap":9920707},{"date":"2026-09-04","current":-0.646034,"twenty":-5.881844,"median":-2.853034,"eighty":-0.862552,"marketCap":11718419},{"date":"2026-09-09","current":-0.627681,"twenty":-5.875972,"median":-2.853034,"eighty":-0.860566,"marketCap":11385510}],"updateTime":1789070633689},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBLG\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640094129","title":"FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2640094129","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640094129?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:00","pubTimestamp":1780484400,"startTime":"0","endTime":"0","summary":"HOUSTON, June  03, 2026  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the dev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305903/0/en/FibroBiologics-Announces-First-Patients-Dosed-in-Phase-1-2-Clinical-Trial-Evaluating-CYWC628-for-the-Treatment-of-Diabetic-Foot-Ulcers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637117263","title":"FibroBiologics presents CYPS317 preclinical psoriasis data showing durable immunomodulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2637117263","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637117263?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:31","pubTimestamp":1779453065,"startTime":"0","endTime":"0","summary":"FibroBiologics disclosed preclinical results for its CYPS317 psoriasis program that were presented at the Society for Investigative Dermatology 2026 Annual Meeting held May 13-15, 2026.In mouse studies, a fibroblast spheroid formulation reduced psoriasis-like disease activity while avoiding systemic immune activation seen with single-cell delivery.In a chronic-relapsing model, booster dosing helped sustain the treatment effect, supporting a repeat-dosing approach for longer-term disease control.The data position CYPS317 as a potential differentiated, systemically administered cell therapy strategy for psoriasis, though it remains at the preclinical stage.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL2y721W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014021.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4588","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","BK4112","FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637311246","title":"Press Release: FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637311246","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637311246?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:30","pubTimestamp":1779453000,"startTime":"0","endTime":"0","summary":"HOUSTON, May 22, 2026  -- FibroBiologics, Inc.  , a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials,  today announced preclinical data from its CYPS317 program for psoriasis presented at the Society for Investigative Dermatology 2026 Annual Meeting, held May 13-15, 2026, in Chicago, Illinois. A link to the poster can be found here.Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immunity, with the IL-23/Th17 axis playing a central role in sustaining disease activity. In an imiquimod-induced psoriasis mouse model, both HDF spheroids and single-cell HDF preparations reduced disease severity; however, spheroids provided a more favorable systemic safety profile by avoiding the innate immune activation observed with single-cell delivery, an important distinction for a cell-based therap","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636075854","title":"Fibrobiologics Inc - Files Provisional Patent Application for Oral Fibroblast Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2636075854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636075854?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:32","pubTimestamp":1779107558,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636075591","title":"FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2636075591","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636075591?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:30","pubTimestamp":1779107400,"startTime":"0","endTime":"0","summary":"HOUSTON, May  18, 2026  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (\"FibroBiologics\"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the developme","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3296634/0/en/FibroBiologics-Files-Patent-Application-for-Oral-Administration-of-Fibroblast-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","FBLG","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634238986","title":"FibroBiologics expands fibroblast-based platform to target Hantavirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2634238986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634238986?lang=en_us&edition=fundamental","pubTime":"2026-05-11 22:42","pubTimestamp":1778510579,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) announced a strategic expansion of its fibroblast-based platform to target Hantavirus. Building on existing preclinical work ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-expands-fibroblast-based-platform-to-target-hantavirus-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-expands-fibroblast-based-platform-to-target-hantavirus-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634924282","title":"Fibrobiologics Shares Down 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634924282","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634924282?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:32","pubTimestamp":1778506370,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O1C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634528195","title":"Fibrobiologics Shares NOW Down 15% Premarket at 99 Cents","url":"https://stock-news.laohu8.com/highlight/detail?id=2634528195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634528195?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:45","pubTimestamp":1778503545,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL4N41O0ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634289722","title":"FibroBiologics expands fibroblast platform to target Hantavirus pulmonary syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2634289722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634289722?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:31","pubTimestamp":1778502684,"startTime":"0","endTime":"0","summary":"FibroBiologics expanded fibroblast-based platform to target Hantavirus pulmonary syndrome, aiming to translate earlier ARDS work into a new development program.Evaluation underway in Hantavirus disease models, focusing on cytokine modulation and reduced endothelial permeability.Exploratory talks planned with regulatory authorities to define a development pathway toward clinical testing in HPS patients.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8Dvq0s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","FBLG","NDAQ","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4588","LU2210150020.SGD","SG9999014039.USD","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634289786","title":"Fibrobiologics Advancing Development of a Fibroblast Treatment for Hantavirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2634289786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634289786?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:30","pubTimestamp":1778502621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O10T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634289780","title":"Fibrobiologics Inc - to Initiate Discussions With Regulators for Hps Clinical Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2634289780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634289780?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:30","pubTimestamp":1778502621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O10T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634928111","title":"FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2634928111","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634928111?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:30","pubTimestamp":1778502600,"startTime":"0","endTime":"0","summary":"Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global CrisisHOUSTON, May  11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBL","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291882/0/en/FibroBiologics-Advancing-Development-of-a-Fibroblast-Treatment-for-Hantavirus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HPS","FBLG","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633878981","title":"FibroBiologics boosts ATM equity offering capacity to USD 7.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633878981","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633878981?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:17","pubTimestamp":1778066236,"startTime":"0","endTime":"0","summary":"FibroBiologics entered at-the-market equity distribution agreement with H.C. Wainwright, allowing sales of common stock from time to time under shelf registration statement.Prospectus supplement increased maximum size of ATM program to aggregate offering price of up to $7.5 million.71,830 shares have been sold under sales agreement to date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL3Cqfl3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633829511","title":"Fibrobiologics Inc - Increases Atm Offering to Aggregate $7.5 Mln on May 5, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633829511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633829511?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:07","pubTimestamp":1778065628,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J0VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633484249","title":"FibroBiologics CEO Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2633484249","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633484249?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"HOUSTON, May  05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the devel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287694/0/en/FibroBiologics-CEO-Issues-Letter-to-Shareholders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633103499","title":"FibroBiologics Grants Stock Options to Key Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2633103499","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633103499?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:01","pubTimestamp":1777982460,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc. ( ($FBLG) ) has issued an update. On May 4, 2026, FibroBiologics, Inc.’s compensation committee granted stock options under it...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-grants-stock-options-to-key-executives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-grants-stock-options-to-key-executives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633177912","title":"FibroBiologics grants CEO 92,410 stock options, executives 61,607 each at $1.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2633177912","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633177912?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:22","pubTimestamp":1777980120,"startTime":"0","endTime":"0","summary":"FibroBiologics granted stock options under its 2022 Stock Plan to CEO Pete O’Heeron for 92,410 common shares, with an exercise price of $1.38 per share.Options covering 61,607 shares each were also issued to CFO Jason D. Davis, Chief Scientific Officer Hamid Khoja, and General Counsel Ruben A. Garcia at the same $1.38 strike.Vesting starts with 25% on first anniversary of May 4, 2026 grant date.Remaining options vest in 36 equal monthly installments, contingent on continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL6w8q00:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633634869","title":"FibroBiologics reports preclinical burn-wound data for fibroblast spheroid therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2633634869","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633634869?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:03","pubTimestamp":1777924991,"startTime":"0","endTime":"0","summary":"FibroBiologics disclosed preclinical burn-wound data already presented, pointing to a rapid shift in wound biology following topical treatment with human dermal fibroblast spheroids.Treated wounds appeared less inflamed, with signs of immune activity moving toward tissue repair rather than persistent inflammation.Biomarker readouts also suggested reduced scar-forming activity, supporting a potential positioning in burn care where long-term scarring drives clinical burden.Management framed results as mechanistic support to expand its wound-care platform to include burn injuries, signaling a broader development strategy beyond core indications.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL8NsGsq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014039.USD","LU2095319765.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","FBLG","BK4585","SG9999014005.SGD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014013.SGD","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955165","title":"FibroBiologics Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955165","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955165?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:04","pubTimestamp":1777899840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 09:04 ET (13:04 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632923953","title":"FibroBiologics releases CYWC628 drug product for Phase 1/2 diabetic foot ulcer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2632923953","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632923953?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:33","pubTimestamp":1777897987,"startTime":"0","endTime":"0","summary":"FibroBiologics released first cGMP batch of investigational CYWC628 drug product to support planned Phase 1/2 clinical trial in diabetic foot ulcers.Batch cleared required safety and quality testing, enabling clinical use and allowing patient enrollment to start.No clinical results have been presented; trial will assess safety, tolerability, and early signs of benefit.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLBxjLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4112","NDAQ","SG9999014013.SGD","BK4588","LU0314104364.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","FBLG","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":126,"code":"91000000","status":"200"}]}}